

## Special Issue

# Advances in the Use of Nanoparticles for Vaccine Platform Development

### Message from the Guest Editor

Nanoparticle-based formulations, such as polymeric, virosomes, and lipid nanoparticles, help in the induction of sufficient immune responses. These nanoparticle vaccine platform delivery systems protect vaccine candidates, improve stability, prevent degradation, and offer adjuvant properties enhancing immunogenicity and targeting antigen presenting cells (APCs). Moreover, activation of dendritic cells, tumor immunotherapy, and use of biomimetic nanoparticles open new possibilities for the fight against infectious diseases, cancer, and other complex diseases. This Special Issue welcomes original research and review articles focusing on the preclinical and clinical development of advanced nanoparticle delivery systems composed of liposomes and lipid-based nanoparticles, polymeric nanoparticles, gold nanoparticles, inorganic nanoparticles, virus-like particles, self-assembled proteins, biomimetic nanoparticles, and other nanoparticles, including carbon-based nanoparticles (carbon nanotubes and graphenes) to trigger specific immune responses and immunological memory for human and veterinary use.

---

### Guest Editor

Prof. Dr. Imran Saleem  
School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK

---

### Deadline for manuscript submissions

closed (31 January 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/151226](https://mdpi.com/si/151226)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).